Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III ...

Roche’s Hemlibra has been approved in an expanded use in haemophilia A in the US, as the Swiss firm seeks to build a new blockbuster franchise in rare diseases. The firm is best known for its ...

Novo Nordisk has bolstered the case for its near-approval hemophilia A drug candidate Mim8, linking the prospect to ...

NHS England has agreed to reimburse Roche’s Hemlibra (emicizumab) in a new group of patients with haemophilia A, widening access to the potentially life-saving drug. Following the commissioning ...

Drugmakers raised the list prices of more than 800 prescription drugs for blood pressure, cancer and other conditions by a median 4% at the start of this year. The modest size of the annual increases ...

Hemlibra was found to ease pain and improve quality of life for hemophilia A patients, even those with long-term joint damage, per a study.

Swiss pharma giant Roche Holding AG RHHBY posted better-than-expected 2024 results and provided an encouraging outlook for 2025. Sales in 2024 totaled $68.7 billion, which beat the Zacks Consensus ...

The top four growth drivers — Vabysmo, Phesgo, Ocrevus and Hemlibra — achieved total sales of CHF 16.9 billion, reflecting an increase of CHF 3.3 billion from that recorded in 2023.